Medication info
Linatop Duo Tablet 2.5/500 mg (Linagliptin, Metformin Hydrochloride)

Linatop Duo Tablet 2.5/500 mg (Linagliptin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Donggu Bio Pharmaceutical Co., Ltd.
Appearance
Bright yellow oval film-coated tablet
Packaging
60 tablets (10 tablets/PTP × 6)
Approval status
Active

MFDS item code 201904462 · Approved 2019.06.28 · Insurance code 657308940

Summary

Main use
Improves blood glucose control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, the starting dose of this medicine is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should take the same doses of linagliptin and metformin that they were previously taking as the initial dose. Patients unable to achieve adequate glycemic control with combination therapy of insulin and metformin: The starting dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia. Patients with renal impairment: This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately.

Ingredients

Manufacturer
Donggu Bio Pharmaceutical Co., Ltd.

Efficacy & effects

Improves blood glucose control in patients with type 2 diabetes mellitus

View approved original text

This medication helps improve blood sugar control in patients with type 2 diabetes who have difficulty managing their blood sugar through diet and exercise, by combining linagliptin and metformin. Specifically, this medicine is used as an adjunct to effectively lower blood sugar levels and assist in diabetes management.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, the starting dose of this medicine is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should take the same doses of linagliptin and metformin that they were previously taking as the initial dose. Patients unable to achieve adequate glycemic control with combination therapy of insulin and metformin: The starting dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia. Patients with renal impairment: This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately.

Precautions

This medication has the potential to cause a serious adverse effect called lactic acidosis, therefore should not be administered to patients with kidney dysfunction or acute illness. Individuals who are allergic to any components of this medication or those with type 1 diabetes, pregnant or breastfeeding women should avoid its use. There is a risk of hypoglycemia, especially when used in conjunction with sulfonylureas or insulin, and dosage adjustments may be necessary in such cases. Kidney function should be monitored regularly, and the medication should be discontinued if renal function declines. Care should also be taken in patients with weak cardiac function or acute heart conditions. If undergoing radiological tests involving iodine contrast agents, the medication should be stopped for a period before and after the test, and kidney function must be assessed. Rare side effects such as acute pancreatitis and blistering skin conditions have been reported, and if continuous abdominal pain or skin blisters occur during treatment, consult a doctor immediately. This medication may cause gastrointestinal disorders, taste disturbances, vitamin B12 deficiency, etc., so routine testing may be necessary during long-term use. Women who are pregnant or planning a pregnancy should not use this medication and consult a physician, and breastfeeding should also be avoided. Older adults are at higher risk of decreased kidney function, thus dosage adjustments and regular monitoring of kidney function are necessary. This medication may interact with other drugs, so it is essential to inform the healthcare provider of any concurrently taken medications. In case of overdose, the risk of lactic acidosis increases, requiring immediate treatment at a hospital, and blood dialysis may be necessary. When storing, keep out of reach of children and avoid moisture.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • taste disorder
  • cough
  • loss of appetite
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
Show 127 more
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesicular pemphigoid
  • severe arthritis with disability
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • reduced vitamin B12 and deficiency
  • cheilitis
  • stomatitis
  • epigastric pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • shingles
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • cerebral infarction
  • speech disorder
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscal injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • anxiety
  • mood disorder
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • benign prostatic hyperplasia
  • itching
  • hypertension
  • hearing loss
  • confusion
  • nocturia
  • dermatitis
  • hyperglycemia
  • dizziness
  • sensory loss
  • osteoarthritis
  • limb pain
  • arthropathy
  • musculoskeletal discomfort
  • myositis
  • myalgia
  • soft tissue mass
  • postmenopausal osteoporosis
  • rotator cuff syndrome
  • increased triglycerides in blood
  • increased urine albumin/creatinine ratio
  • positive urine leukocytes
  • decreased hemoglobin
  • increased blood potassium
  • increased blood creatinine
  • increased blood creatine phosphokinase
  • increased ALT
  • increased AST
  • male pattern baldness
  • hyperhidrosis
  • hair loss
  • anxiety
  • mood disorder
  • insomnia
  • depression
  • palpitations
  • dry eye
  • cataract
  • ocular discomfort
  • allergic conjunctivitis
  • vitreous hemorrhage
  • erectile dysfunction
  • thyroid goiter
  • thyroid nodule
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, therefore, it should be stored tightly closed. It is best stored at room temperature between 1 to 30 degrees Celsius. This way, the effectiveness of the medication can be maintained for a longer period.

Appearance and packaging

Appearance

Bright yellow oval film-coated tablet

Package unit

60 tablets (10 tablets/PTP × 6)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.